Parrish Capital’s Gilead Sciences GILD Stock Holding History

Parrish Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.17M	Sell	22,746 -1,149	-5%	-$161K	2.83%	3
2025 Q4	$2.93M	Buy	+23,895	New	+$2.9M	2.66%	5

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Parrish Capital's GILD Position: Q1 2026 in Review

Parrish Capital reduced its Gilead Sciences (GILD) stake by 4.8% in Q1 2026, selling an estimated $161K and leaving 22,746 shares worth $3.17M. The position accounts for 2.83% of the portfolio, ranked #3.

Parrish Capital first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Parrish Capital held 22,746 shares of Gilead Sciences worth $3.17M as of Q1 2026.
Parrish Capital sold 1,149 Gilead Sciences shares in Q1 2026, an estimated $161K.
Gilead Sciences made up 2.83% of Parrish Capital's portfolio in Q1 2026, its #3 holding.
Parrish Capital first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Parrish Capital's 13F filing for Q1 2026, filed 28 Apr 2026.